BMGF

Field friendly biometry to ease cohort studies in resource-limited settings: application to the Test and Treat for onchocerciasis project in Central Cameroon

Can a biometric recognition system, in the context of “Test and Treat”, facilitate individual follow-up by linking participant data at different time-points?

Countries: Cameroon
Diseases: Loiasis | Onchocerciasis

District Mapping Onchocerciasis, Lymphatic Filariasis, and Loiasis in DRC

Pilot a strategy for mapping and treating Onchocerciasis and Lymphatic Filariasis in Loa loa coendemic areas

Countries: Dem. Rep. of Congo

Ov16 AP ELISA comparison in Cameroon

How does the performance of the AP ELISA compare to the Ov16 SD ELISA, when conducted in a country lab?

Countries: Cameroon
Diseases: Onchocerciasis

Is Preventive Chemotherapy for NTDs Really “Pro-Poor?”: Insights from the Demographic and Health Surveys

To use DHS data from 40 countries to examine the extent to which deworming of children 1-4 years is associated with: 1) a range of individual- and family-related socioeconomic indicators, including wealth quintile and maternal education; and 2) access to health systems that could provide opportunities for deworming, independent of family-level socioeconomic status.

Countries:

Coverage Evaluation Survey and Supervisor's Coverage Tool Implementation in Kenya for Triple Drug Therapy

Coverage Evaluation Survey

Is coverage, or a combination of coverage and systematic non-compliance, more effective than a diagnostic tool at predicting when it is safe to stop triple drug therapy?

Supervisor's Coverage Tool

Is the use of the SCT during IDA feasible to implement at the sub-county scale and does it lead to increased coverage?

Countries: Kenya

Operational research to develop an M&E strategy to guide triple drug stopping decisions for lymphatic filariasis in Egypt

What is the indicator(s) and accompanying monitoring and evaluation (M&E) strategy that enables country programs to determine when the risk of ongoing transmission of LF has been reduced so that IDA can be stopped with little risk of resurgence of transmission?

Countries: Egypt

Operational research to develop an M&E strategy to guide triple drug stopping decisions for lymphatic filariasis in Kenya

What is the indicator(s) and accompanying M&E strategy that enables country programs to determine when the risk of ongoing transmission of LF has been reduced so that IDA can be stopped with little risk of resurgence of transmission?

Countries: Kenya

Processing Ov16 ELISA for Oncho Elimination Mapping

Would the same programmatic decisions for Oncho Elimination Mapping be made based off of the Ov16 rapid diagnostic test results as compared to the Ov16 SD ELISA results?

Countries: Kenya | Malawi | Burundi
Diseases: Onchocerciasis

Operational research to develop an M&E strategy to guide triple drug stopping decisions for lymphatic filariasis in Samoa

What is the indicator(s) and accompanying M&E strategy that enables country programs to determine when the risk of ongoing transmission of LF has been reduced so that IDA can be stopped with little risk of resurgence of transmission?

Countries: Samoa

Development of a geostatistical mapping tool to improve decision-making for Loa loa and LF

Can serological markers for NTDs (particularly Loa loa and Lymphatic filariasis) be incorporated into geostatistical maps and used to guide program decisions around treatment and surveillance?

Pages